LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: Hindawi Publishing Corporation
Journal: International Journal of Genomics
Languages: English
Types: Article
Subjects: QH426-470, Review Article, Article Subject, Genetics

Classified by OpenAIRE into

mesheuropmc: cardiovascular diseases, musculoskeletal system, cardiovascular system, complex mixtures
Cardiovascular disease is a leading cause of death in both humans and dogs. Dilated cardiomyopathy (DCM) accounts for a large number of these cases, reported to be the third most common form of cardiac disease in humans and the second most common in dogs. In human studies of DCM there are more than 50 genetic loci associated with the disease. Despite canine DCM having similar disease progression to human DCM studies into the genetic basis of canine DCM lag far behind those of human DCM. In this review the aetiology, epidemiology, and clinical characteristics of canine DCM are examined, along with highlighting possible different subtypes of canine DCM and their potential relevance to human DCM. Finally the current position of genetic research into canine and human DCM, including the genetic loci, is identified and the reasons many studies may have failed to find a genetic association with canine DCM are reviewed.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] J. M. Fleming, K. E. Creevy, and D. E. L. Promislow, “Mortality in north american dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death,” Journal of Veterinary Internal Medicine, vol. 25, no. 2, pp. 187-198, 2011.
    • [2] C. D. Mathers and D. Loncar, “Projections of global mortality and burden of disease from 2002 to 2030,” PLoS Medicine, vol. 3, no. 11, article e442, 2006.
    • [3] A. Egenvall, B. N. Bonnett, and J. Ha¨ggstro¨m, “Heart disease as a cause of death in insured Swedish dogs younger than 10 years of age,” Journal of Veterinary Internal Medicine, vol. 20, no. 4, pp. 894-903, 2006.
    • [4] H. Raju, C. Alberg, G. S. Sagoo, H. Burton, and E. R. Behr, “Inherited cardiomyopathies,” British Medical Journal, vol. 343, Article ID d6966, 2011.
    • [5] R. E. Hershberger, A. Morales, and J. D. Siegfried, “Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals,” Genetics in Medicine, vol. 12, no. 11, pp. 655-667, 2010.
    • [6] T.-B. Mausberg, G. Wess, J. Simak et al., “A locus on chromosome 5 is associated with dilated cardiomyopathy in doberman pinschers,” PLoS ONE, vol. 6, no. 5, Article ID e20042, 2011.
    • [7] J. A. Dixon and F. G. Spinale, “Large animal models of heart failure: a critical link in the translation of basic science to clinical practice,” Circulation: Heart Failure, vol. 2, no. 3, pp. 262-271, 2009.
    • [8] F. G. Akar, R. C. Wu, G. J. Juang et al., “Molecular mechanisms underlying K+ current downregulation in canine tachycardiainduced heart failure,” eTh American Journal of PhysiologyHeart and Circulatory Physiology, vol. 288, no. 6, pp. H2887- H2896, 2005.
    • [9] M. Argenziano and M. L. Dickstein, “Cardiovascular eefcts of inhaled nitric oxide in a canine model of cardiomyopathy,” eTh Annals of oThracic Surgery , vol. 69, no. 5, pp. 1644-1645, 2000.
    • [10] Y. Toyoda, M. Okada, and M. A. Kashem, “A canine model of dilated cardiomyopathy induced by repetitive intracoronary doxorubicin administration,” Journal of oThracic and Cardiovascular Surgery, vol. 115, no. 6, pp. 1367-1373, 1998.
    • [11] K. Huntington, P. Picard, G. Moe, D. J. Stewart, A. Albernaz, and J. C. Monge, “Increased cardiac and pulmonary endothelin1 mRNA expression in canine pacing-induced heart failure,” Journal of Cardiovascular Pharmacology, vol. 31, no. 1, pp. S424- S426, 1998.
    • [12] M. Hongo, T. Ryoke, and J. Ross Jr., “Animal models of heart failure: recent developments and perspectives,” Trends in Cardiovascular Medicine, vol. 7, no. 5, pp. 161-167, 1997.
    • [13] O. P. Guttmann, S. A. Mohiddin, and P. M. Elliott, “Almanac 2014: cardiomyopathies,” Heart, vol. 100, no. 10, pp. 756-764, 2014.
    • [14] E. M. McNally, J. R. Golbus, and M. J. Puckelwartz, “Genetic mutations and mechanisms in dilated cardiomyopathy,” eTh Journal of Clinical Investigation, vol. 123, no. 1, pp. 19-26, 2013.
    • [15] N. G. Mahon, R. T. Murphy, C. A. MacRae, A. L. Caforio, P. M. Elliott, and W. J. McKenna, “Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease,” Annals of Internal Medicine, vol. 143, no. 2, pp. 108-115, 2005.
    • [16] M. K. Baig, J. H. Goldman, A. L. P. Caforio, A. S. Coonar, P. J. Keeling, and W. J. McKenna, “Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relative and may represent early disease,” Journal of the American College of Cardiology, vol. 31, no. 1, pp. 195-201, 1998.
    • [17] S. E. Brownlie and M. A. Cobb, “Observations on the development of congestive heart failure in Irish wolofhunds with dilated cardiomyopathy,” Journal of Small Animal Practice, vol. 40, no. 8, pp. 371-377, 1999.
    • [18] J. Dukes-McEwan, M. Borgarelli, A. Tidholm, A. C. Vollmar, and J. Ha¨ggstro¨m, “Proposed guidelines for the diagnosis of canine idiopathic dilated cardiomyopathy,” Journal of Veterinary Cardiology, vol. 5, no. 2, pp. 7-19, 2003.
    • [19] A. Tidholm, J. Ha¨ggstro¨m, M. Borgarelli, and A. Tarducci, “Canine idiopathic dilated cardiomyopathy. Part I: Aetiology, clinical characteristics, epidemiology and pathology,,” Veterinary Journal, vol. 162, no. 2, pp. 92-107, 2001.
    • [20] S. Lehrke, D. Lossnitzer, M. Scho¨b et al., “Use of cardiovascular magnetic resonance for risk straticfiation in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy,” Heart, vol. 97, no. 9, pp. 727-732, 2011.
    • [21] A. D. Petric, P. Stabej, and A. Zemva, “Dilated cardiomyopathy in doberman pinschers: survival, causes of death and a pedigree review in a related line,” Journal of Veterinary Cardiology, vol. 4, no. 1, pp. 17-24, 2002.
    • [22] A. C. Vollmar, “eTh prevalence of cardiomyopathy in the Irish wolfhound: a clinical study of 500 dogs,” Journal of the American Animal Hospital Association, vol. 36, no. 2, pp. 125-132, 2000.
    • [23] M. W. S. Martin, M. J. S. Johnson, G. Strehlau, and J. N. King, “Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases,” Journal of Small Animal Practice, vol. 51, no. 8, pp. 428-436, 2010.
    • [24] J. L. Jeefries and J. A. Towbin, “Dilated cardiomyopathy,” eTh Lancet, vol. 375, no. 9716, pp. 752-762, 2010.
    • [25] M. Merlo, A. Pivetta, B. Pinamonti et al., “Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years,” European Journal of Heart Failure, vol. 16, no. 3, pp. 317- 324, 2014.
    • [26] D. O. Taylor, J. Stehlik, L. B. Edwards et al., “Registry of the international society for heart and lung transplantation: twentysixth oficial adult heart transplant report-2009,” Journal of Heart and Lung Transplantation, vol. 28, no. 10, pp. 1007-1022, 2009.
    • [27] J. D. McEwan, “Canine dilated cardiomyopathy 2. Pathophysiology and treatment,” In Practice, vol. 22, no. 10, pp. 620-628, 2000.
    • [28] M. Borgarelli, A. Tarducci, A. Tidholm, and J. Ha¨ggstro¨m, “Canine idiopathic dilated cardiomyopathy. Part II: pathophysiology and therapy,” Veterinary Journal, vol. 162, no. 3, pp. 182- 195, 2001.
    • [29] N. J. Summerfield, A. Boswood, M. R. O'Grady et al., “Eficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study),” Journal of Veterinary Internal Medicine, vol. 26, no. 6, pp. 1337-1349, 2012.
    • [30] A. Tidholm and L. Jo¨nsson, “A retrospective study of canine dilated cardiomyopathy (189 cases),” Journal of the American Animal Hospital Association, vol. 33, no. 6, pp. 544-550, 1997.
    • [31] C. A. Calvert, C. W. Pickus, G. J. Jacobs, and J. Brown, “Signalment, survival, and prognostic factors in Doberman pinschers with end-stage cardiomyopathy,” Journal of Veterinary Internal Medicine, vol. 11, no. 6, pp. 323-326, 1997.
    • [32] A. Tidholm and L. Jo¨nsson, “Histologic characterization of canine dilated cardiomyopathy,” Veterinary Pathology, vol. 42, no. 1, pp. 1-8, 2005.
    • [33] K. M. Meurs, M. W. Miller, and N. A. Wright, “Clinical features of dilated cardiomyopathy in Great Danes and results of a pedigree analysis: 17 cases (1990-2000),” Journal of the American Veterinary Medical Association, vol. 218, no. 5, pp. 729-732, 2001.
    • [34] M. M. Sleeper, P. S. Henthorn, C. Vijayasarathy et al., “Dilated cardiomyopathy in juvenile Portuguese water dogs,” Journal of Veterinary Internal Medicine, vol. 16, no. 1, pp. 52-62, 2002.
    • [35] K. M. Meurs, P. R. Fox, M. Norgard et al., “A prospective genetic evaluation of familial dilated cardiomyopathy in the Doberman pinscher,” Journal of Veterinary Internal Medicine, vol. 21, no. 5, pp. 1016-1020, 2007.
    • [36] L. Lobo, J. Carvalheira, N. Canada, C. Bussadori, J. L. Gomes, and A. M. R. Faustino, “Histologic characterization of dilated cardiomyopathy in Estrela mountain dogs,” Veterinary Pathology, vol. 47, no. 4, pp. 637-642, 2010.
    • [37] H. Aupperle, I. Marz, K. Baldauf, N. Roggon, and J. G. Kresken, “Pathology of DCM in Great Danes,” Journal of Veterinary Internal Medicine, vol. 28, no. 2, p. 730, 2014.
    • [38] H. M. Stephenson, S. Fonfara, J. Lo´pez-Alvarez, P. Cripps, and J. Dukes-McEwan, “Screening for dilated cardiomyopathy in Great Danes in the United Kingdom,” Journal of Veterinary Internal Medicine, vol. 26, no. 5, pp. 1140-1147, 2012.
    • [39] A. Posafalvi, J. C. Herkert, R. J. Sinke et al., “Clinical utility gene card for: dilated cardiomyopathy (CMD),” European Journal of Human Genetics, vol. 21, no. 10, p. 1185, 2013.
    • [40] G. W. Dec and V. Fuster, “Idiopathic dilated cardiomyopathy,” ehT New England Journal of Medicine , vol. 331, no. 23, pp. 1564- 1575, 1994.
    • [41] J. Dukes-McEwan and I. J. Jackson, “eTh promises and problems of linkage analysis by using the current canine genome map,” Mammalian Genome, vol. 13, no. 11, pp. 667-672, 2002.
    • [42] O. Distl, A. C. Vollmar, C. Broschk, H. Hamann, and P. R. Fox, “Complex segregation analysis of dilated cardiomyopathy (DCM) in Irish wolofhunds,” Heredity, vol. 99, no. 4, pp. 460- 465, 2007.
    • [43] P. Werner, M. G. Raducha, U. Prociuk, M. M. Sleeper, T. J. van Winkle, and P. S. Henthorn, “A novel locus for dilated cardiomyopathy maps to canine chromosome 8,” Genomics, vol. 91, no. 6, pp. 517-521, 2008.
    • [44] D. M. Dambach, A. Lannon, M. M. Sleeper, and J. Buchanan, “Familial dilated cardiomyopathy of young Portuguese water dogs,” Journal of Veterinary Internal Medicine, vol. 13, no. 1, pp. 65-71, 1999.
    • [45] M. W. S. Martin, M. J. Staofrd Johnson, and B. Celona, “Canine dilated cardiomyopathy: a retrospective study of signalment, presentation and clinical findings in 369 cases,” Journal of Small Animal Practice, vol. 50, no. 1, pp. 23-29, 2009.
    • [46] L. Mestroni, C. Rocco, D. Gregori et al., “Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity,” Journal of the American College of Cardiology, vol. 34, no. 1, pp. 181-190, 1999.
    • [47] J. A. Towbin, A. M. Lowe, S. D. Colan et al., “Incidence, causes, and outcomes of dilated cardiomyopathy in children,” Journal of the American Medical Association, vol. 296, no. 15, pp. 1867- 1876, 2006.
    • [48] D. Jacoby and W. J. McKenna, “Genetics of inherited cardiomyopathy,” European Heart Journal, vol. 33, no. 3, pp. 296-304, 2012.
    • [49] L. Mestroni and M. R. G. Taylor, “Genetics and genetic testing of dilated cardiomyopathy: a new perspective,” Discovery Medicine, vol. 15, no. 80, pp. 43-49, 2013.
    • [50] A. Morales and R. E. Hershberger, “Genetic evaluation of dilated cardiomyopathy,” Current Cardiology Reports, vol. 15, no. 7, article 375, 2013.
    • [51] N. Hamdani, V. Kooij, S. van Dijk et al., “Sarcomeric dysfunction in heart failure,” Cardiovascular Research, vol. 77, no. 4, pp. 649-658, 2008.
    • [52] E. Frixione, “Recurring views on the structure and function of the cytoskeleton: a 300-year epic,” Cell Motility and the Cytoskeleton, vol. 46, no. 2, pp. 73-94, 2000.
    • [53] S. Hein, S. Kostin, A. Heling, Y. Maeno, and J. Schaper, “eTh role of the cytoskeleton in heart failure,” Cardiovascular Research, vol. 45, no. 2, pp. 273-278, 2000.
    • [54] I. G. Macara, “Transport into and out of the nucleus,” Microbiology and Molecular Biology Reviews, vol. 65, no. 4, pp. 570-594, 2001.
    • [55] M. W. Hetzer, “eTh nuclear envelope,” Cold Spring Harbor Perspectives in Biology, vol. 2, no. 3, Article ID a000539, 2010.
    • [56] K. J. Green and C. A. Gaudry, “Are desmosomes more than tethers for intermediate filaments?” Nature Reviews Molecular Cell Biology, vol. 1, no. 3, pp. 208-216, 2000.
    • [57] R. DiPolo and L. Beauge´, “Sodium/calcium exchanger: inuflence of metabolic regulation on ion carrier interactions,” Physiological Reviews, vol. 86, no. 1, pp. 155-203, 2006.
    • [58] D. S. Latchman, “Transcription factors: an overview,” eTh International Journal of Biochemistry & Cell Biology, vol. 29, no. 12, pp. 1305-1312, 1997.
    • [59] G. Wess, A. Schulze, V. Butz et al., “Prevalence of dilated cardiomyopathy in Doberman Pinschers in various age groups,” Journal of Veterinary Internal Medicine, vol. 24, no. 3, pp. 533- 538, 2010.
    • [60] K. M. Meurs, S. Lahmers, B. W. Keene et al., “A splice site mutation in a gene encoding for PDK4, a mitochondrial protein, is associated with the development of dilated cardiomyopathy in the Doberman pinscher,” Human Genetics, vol. 131, no. 8, pp. 1319-1325, 2012.
    • [61] U. Philipp, A. Vollmar, J. Ha¨ggstro¨m, A. oThmas, and O. Distl, “Multiple loci are associated with dilated cardiomyopathy in irish wolofhunds,” PLoS ONE, vol. 7, no. 6, Article ID e36691, 2012.
    • [62] K. M. Meurs, J. A. Stern, D. D. Sisson et al., “Association of dilated cardiomyopathy with the striatin mutation genotype in boxer dogs,” Journal of Veterinary Internal Medicine, vol. 27, no. 6, pp. 1437-1440, 2013.
    • [63] S. J. Schatzberg, N. J. Olby, M. Breen et al., “Molecular analysis of a spontaneous dystrophin 'knockout' dog,” Neuromuscular Disorders, vol. 9, no. 5, pp. 289-295, 1999.
    • [64] U. Philipp, C. Broschk, A. Vollmar, and O. Distl, “Evaluation of tafazzin as candidate for dilated cardiomyopathy in Irish wolofhunds,” Journal of Heredity, vol. 98, no. 5, pp. 506-509, 2007.
    • [65] A. C. Wiersma, P. A. Leegwater, B. A. van Oost, W. E. Ollier, and J. Dukes-McEwan, “Canine candidate genes for dilated cardiomyopathy: annotation of and polymorphic markers for 14 genes,” BMC Veterinary Research, vol. 3, article 28, 2007.
    • [66] P. Stabej, P. A. Leegwater, A. A. Stokhof, A. Domanjko-Petricˇ, and B. A. van Oost, “Evaluation of the phospholamban gene in purebred large-breed dogs with dilated cardiomyopathy,” American Journal of Veterinary Research, vol. 66, no. 3, pp. 432- 436, 2005.
    • [67] K. M. Meurs, K. P. Hendrix, and M. M. Norgard, “Molecular evaluation of vfie cardiac genes in Doberman Pinschers with dilated cardiomyopathy,” American Journal of Veterinary Research, vol. 69, no. 8, pp. 1050-1053, 2008.
    • [68] P. Stabej, S. Imholz, S. A. Versteeg et al., “Characterization of the canine desmin (DES) gene and evaluation as a candidate gene for dilated cardiomyopathy in the Dobermann,” Gene, vol. 340, no. 2, pp. 241-249, 2004.
    • [69] A. C. Wiersma, P. Stabej, P. A. J. Leegwater, B. A. van Oost, W. E. Ollier, and J. Dukes-McEwan, “Evaluation of 15 candidate genes for dilated cardiomyopathy in the Newfoundland dog,” Journal of Heredity, vol. 99, no. 1, pp. 73-80, 2008.
    • [70] T. A. Manolio, “Genomewide association studies and assessment of the risk of disease,” eTh New England Journal of Medicine, vol. 363, no. 2, pp. 166-176, 2010.
    • [71] S. Simpson, J. Edwards, R. D. Emes, M. A. Cobb, N. P. Mongan, and C. S. Rutland, “A predictive model for canine dilated cardiomyopathy-a meta-analysis of Doberman Pinscher data,” PeerJ, vol. 3, article e842, 2015.
    • [72] F. Faul, E. Erdfelder, A. Buchner, and A.-G. Lang, “Statistical power analyses using G* power 3.1: tests for correlation and regression analyses,” Behavior Research Methods, vol. 41, no. 4, pp. 1149-1160, 2009.
    • [73] E. K. Karlsson and K. Lindblad-Toh, “Leader of the pack: gene mapping in dogs and other model organisms,” Nature Reviews Genetics, vol. 9, no. 9, pp. 713-725, 2008.
    • [74] J. P. Wagner, eTh Boxer , 1939.
    • [75] N. Harpster, “Boxer cardiomyopathy,” in Current Veterinary ehTrapy VIII , W.B. Saunders Company, Philadelphia, Pa, USA, 1983.
    • [76] P. Gruenig, eTh Doberman Pinscher: History and Development of the Breed, Orange Judd Publishing Company Inc, 1939.
    • [77] K. M. Meurs, A. L. Magnon, A. W. Spier, M. W. Miller, L. B. Lehmkuhl, and J. A. Towbin, “Evaluation of the cardiac actin gene in Doberman Pinschers with dilated cardiomyopathy,” American Journal of Veterinary Research, vol. 62, no. 1, pp. 33- 36, 2001.
    • [78] M. Owczarek-Lipska, T.-B. Mausberg, H. Stephenson, J. DukesMcEwan, G. Wess, and T. Leeb, “A 16-bp deletion in the canine PDK4 gene is not associated with dilated cardiomyopathy in a European cohort of Doberman Pinschers,” Animal Genetics, vol. 44, no. 2, p. 239, 2013.
    • [79] J. Samaha, eTh New Complete Irish Wolofhund House, 1991.
    • [80] M. Jansson and L. Laikre, “Recent breeding history of dog breeds in Sweden: modest rates of inbreeding, extensive loss of genetic diversity and lack of correlation between inbreeding and health,” Journal of Animal Breeding and Genetics, vol. 131, no. 2, pp. 153-162, 2014.
    • [81] M. Bienengraeber, T. M. Olson, V. A. Selivanov et al., “ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating,” Nature Genetics, vol. 36, no. 4, pp. 382-387, 2004.
    • [82] T. M. Olson, V. V. Michels, S. N. iThbodeau, Y.-S. Tai, and M. T. Keating, “Actin mutations in dilated cardiomyopathy, a heritable form of heart failure,” Science, vol. 280, no. 5364, pp. 750-752, 1998.
    • [83] B. Mohapatra, S. Jimenez, J. H. Lin et al., “Mutations in the muscle LIM protein and -actinin-2 genes in dilated cardiomyopathy and endocardial bfiroelastosis,” Molecular Genetics and Metabolism, vol. 80, no. 1-2, pp. 207-215, 2003.
    • [84] M. Moulik, M. Vatta, S. H. Witt et al., “ANKRD1, the gene encoding cardiac ankyrin repeat protein, is a novel dilated cardiomyopathy gene,” Journal of the American College of Cardiology, vol. 54, no. 4, pp. 325-333, 2009.
    • [85] N. Norton, D. Li, M. J. Rieder et al., “Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy,” eTh American Journal of Human Genetics, vol. 88, no. 3, pp. 273-282, 2011.
    • [86] E. Villard, C. Perret, F. Gary et al., “A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy,” European Heart Journal, vol. 32, no. 9, pp. 1065-1076, 2011.
    • [87] T. Arimura, T. Ishikawa, S. Nunoda, S. Kawai, and A. Kimura, “Dilated cardiomyopathy-associated BAG3 mutations impair Z-disc assembly and enhance sensitivity to apoptosis in cardiomyocytes,” Human Mutation, vol. 32, no. 12, pp. 1481-1491, 2011.
    • [88] M. Catteruccia, T. Sanna, F. M. Santorelli et al., “Rippling muscle disease and cardiomyopathy associated with a mutation in the CAV3 gene,” Neuromuscular Disorders, vol. 19, no. 11, pp. 779- 783, 2009.
    • [89] L. Zhang, A. Hu, H. Yuan et al., “A missense mutation in the CHRM2 gene is associated with familial dilated cardiomyopathy,” Circulation Research, vol. 102, no. 11, pp. 1426-1432, 2008.
    • [90] N. Inagaki, T. Hayashi, T. Arimura et al., “ B-crystallin mutation in dilated cardiomyopathy,” Biochemical and Biophysical Research Communications, vol. 342, no. 2, pp. 379-386, 2006.
    • [91] J. Erdmann, S. Hassfeld, H. Kallisch, E. Fleck, and V. RegitzZagrose, “Genetic variants in the promoter (g983G>T) and coding region (A92T) of the human cardiotrophin-1 gene (CTF1) in patients with dilated cardiomyopathy,” Human Mutation, vol. 16, no. 5, p. 448, 2000.
    • [92] J. Schaper, R. Froede, S. Hein et al., “Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy,” Circulation, vol. 83, no. 2, pp. 504-514, 1991.
    • [93] D. Li, T. Tapscoft, O. Gonzalez et al., “Desmin mutation responsible for idiopathic dilated cardiomyopathy,” Circulation, vol. 100, no. 5, pp. 461-464, 1999.
    • [94] F. Muntoni, M. Cau, A. Ganau et al., “Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy,” eTh New England Journal of Medicine , vol. 329, no. 13, pp. 921-925, 1993.
    • [95] R. Ortiz-Lopez, H. Li, J. Su, V. Goytia, and J. A. Towbin, “Evidence for a dystrophin missense mutation as a cause of Xlinked dilated cardiomyopathy,” Circulation, vol. 95, no. 10, pp. 2434-2440, 1997.
    • [96] K. M. Davey, J. S. Parboosingh, D. R. McLeod et al., “Mutation of DNAJC19, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition,” Journal of Medical Genetics, vol. 43, no. 5, pp. 385-393, 2006.
    • [97] D. J. Lefeber, A. P. M. de Brouwer, E. Morava et al., “Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation,” PLoS Genetics, vol. 7, no. 12, Article ID e1002427, 2011.
    • [98] P. Elliott, C. O'Mahony, P. Syrris et al., “Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopathy,” Circulation: Cardiovascular Genetics, vol. 3, no. 4, pp. 314-322, 2010.
    • [99] M. G. Posch, M. J. Posch, C. Geier et al., “A missense variant in desmoglein-2 predisposes to dilated cardiomyopathy,” Molecular Genetics and Metabolism, vol. 95, no. 1-2, pp. 74-80, 2008.
    • [100] E. E. Norgett, S. J. Hatsell, L. Carvajal-Huerta et al., “Recessive mutation in desmoplakin disrupts desmoplakin-intermediate iflament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma,” Human Molecular Genetics, vol. 9, no. 18, pp. 2761-2766, 2000.
    • [101] J. Scho¨nberger, L. Wang, J. T. Shin et al., “Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss,” Nature Genetics, vol. 37, no. 4, pp. 418-422, 2005.
    • [102] T. Arimura, T. Hayashi, Y. Matsumoto et al., “Structural analysis of four and half LIM protein-2 in dilated cardiomyopathy,” Biochemical and Biophysical Research Communications, vol. 357, no. 1, pp. 162-167, 2007.
    • [103] T. Murakami, Y. K. Hayashi, S. Noguchi et al., “Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness,” Annals of Neurology, vol. 60, no. 5, pp. 597-602, 2006.
    • [104] T. Mu¨ller, M. Krasnianski, R. Witthaut, M. Deschauer, and S. Zierz, “Dilated cardiomyopathy may be an early sign of the C826A Fukutin-related protein mutation,” Neuromuscular Disorders, vol. 15, no. 5, pp. 372-376, 2005.
    • [105] P. Minoretti, M. Arra, E. Emanuele et al., “A W148R mutation in the human FOXD4 gene segregating with dilated cardiomyopathy, obsessive-compulsive disorder, and suicidality,” International Journal of Molecular Medicine, vol. 19, no. 3, pp. 369-372, 2007.
    • [106] J. L. eThis, K. M. Sharpe, M. E. Matsumoto et al., “Homozygosity mapping and exome sequencing reveal GATAD1 mutation in autosomal recessive dilated cardiomyopathy,” Circulation: Cardiovascular Genetics, vol. 4, no. 6, pp. 585-594, 2011.
    • [107] B. Meder, F. Ru¨hle, T. Weis et al., “A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy,” European Heart Journal, vol. 35, no. 16, pp. 1069-1077, 2014.
    • [108] S. Pankuweit, V. Ruppert, T. Jo´nsdo´ttir, H.-H. Mu¨ller, and T. Meyer, “eTh HLA class II allele DQB1 *0309 is associated with dilated cardiomyopathy,” Gene, vol. 531, no. 2, pp. 180-183, 2013.
    • [109] K. Stark, U. B. Esslinger, W. Reinhard et al., “Genetic association study identiefis HSPB7 as a risk gene for idiopathic dilated cardiomyopathy,” PLoS genetics, vol. 6, no. 10, 2010.
    • [110] R. Kno¨ll, R. Postel, J. Wang et al., “Laminin-alpha4 and integrinlinked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells,” Circulation, vol. 116, no. 5, pp. 515-525, 2007.
    • [111] N. Carboni, G. Marrosu, M. Porcu et al., “Dilated cardiomyopathy with conduction defects in a patient with partial merosin deficiency due to mutations in the laminin- 2-chain gene: a chance association or a novel phenotype?” Muscle & Nerve, vol. 44, no. 5, pp. 826-828, 2011.
    • [112] B. J. Maron, W. C. Roberts, M. Arad et al., “Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy,” eTh Journal of the American Medical Association, vol. 301, no. 12, pp. 1253- 1259, 2009.
    • [113] T. Arimura, T. Hayashi, H. Terada et al., “A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding afinity to protein kinase C,” ehT Journal of Biological Chemistry, vol. 279, no. 8, pp. 6746-6752, 2004.
    • [114] D. Fatkin, C. Macrae, T. Sasaki et al., “Missense mutations in the rod domain of the lamin A/C gene as causes of dilated
    • [122] L. S. Matsa, A. Rangaraju, V. Vengaldas et al., “Haplotypes of NOS3 gene polymorphisms in dilated cardiomyopathy,” PLoS ONE, vol. 8, no. 7, Article ID e70523, 2013.
    • [123] K. Haghighi, F. Kolokathis, L. Pater et al., “Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical diefrence between mouse and human,” Journal of Clinical Investigation, vol. 111, no. 6, pp. 869-876, 2003.
    • [124] A.-K. Arndt, S. Schafer, J.-D. Drenckhahn et al., “Fine mapping of the 1p36 deletion syndrome identifies mutation of PRDM16 as a cause of cardiomyopathy,” American Journal of Human Genetics, vol. 93, no. 1, pp. 67-77, 2013.
    • [125] D. Li, S. B. Parks, J. D. Kushner et al., “Mutations of presenilin genes in dilated cardiomyopathy and heart failure,” eTh American Journal of Human Genetics, vol. 79, no. 6, pp. 1030-1039, 2006.
    • [126] K. M. Brauch, M. L. Karst, K. J. Herron et al., “Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy,” Journal of the American College of Cardiology, vol. 54, no. 10, pp. 930-941, 2009.
    • [127] Z. A. Bhuiyan, M. P. van den Berg, J. P. van Tintelen et al., “Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features,” Circulation, vol. 116, no. 14, pp. 1569-1576, 2007.
    • [128] W. P. McNair, L. Ku, M. R. G. Taylor et al., “SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia,” Circulation, vol. 110, no. 15, pp. 2163-2167, 2004.
    • [129] A. Levitas, E. Muhammad, G. Harel et al., “Familial neonatal isolated cardiomyopathy caused by a mutation in the flavoprotein subunit of succinate dehydrogenase,” European Journal of Human Genetics, vol. 18, no. 10, pp. 1160-1165, 2010.
    • [130] S. Tsubata, K. R. Bowles, M. Vatta et al., “Mutations in the human -sarcoglycan gene in familial and sporadic dilated cardiomyopathy,” Journal of Clinical Investigation, vol. 106, no. 5, pp. 655-662, 2000.
    • [131] Q. Zhang, C. Bethmann, N. F. Worth et al., “Nesprin-1 and -2 are involved in the pathogenesis of Emery-Dreifuss muscular dystrophy and are critical for nuclear envelope integrity,” Human Molecular Genetics, vol. 16, no. 23, pp. 2816-2833, 2007.
    • [132] S. Bione, P. D'Adamo, E. Maestrini, A. K. Gedeon, P. A. Bolhuis, and D. Toniolo, “A novel X-linked gene, G4.5. is responsible for Barth syndrome,” Nature Genetics, vol. 12, no. 4, pp. 385-389, 1996.
    • [133] E. P. Kirk, M. Sunde, M. W. Costa et al., “Mutations in cardiac T-box factor gene TBX20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy,” American Journal of Human Genetics, vol. 81, no. 2, pp. 280-291, 2007.
    • [134] T. Hayashi, T. Arimura, M. Itoh-Satoh et al., “Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy,” Journal of the American College of Cardiology, vol. 44, no. 11, pp. 2192-2201, 2004.
    • [135] M. R. G. Taylor, D. Slavov, A. Gajewski et al., “yThmopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy,” Human Mutation, vol. 26, no. 6, pp. 566-574, 2005.
    • [136] R. T. Murphy, J. Mogensen, A. Shaw, T. Kubo, S. Hughes, and W. J. McKenna, “Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy,” eTh Lancet , vol. 363, no. 9406, pp. 371-372, 2004.
    • [137] M. Kamisago, S. D. Sharma, S. R. DePalma et al., “Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy,” ehT New England Journal of Medicine , vol. 343, no. 23, pp. 1688- 1696, 2000.
    • [138] D. Sibbing, A. Pfeufer, T. Perisic et al., “Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy,” European Heart Journal, vol. 32, no. 9, pp. 1121-1133, 2011.
    • [139] B. Gerull, M. Gramlich, J. Atherton et al., “Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy,” Nature Genetics, vol. 30, no. 2, pp. 201-204, 2002.
    • [140] T. M. Olson, S. Illenberger, N. Y. Kishimoto, S. Huttelmaier, M. T. Keating, and B. M. Jockusch, “Metavinculin mutations alter actin interaction in dilated cardiomyopathy,” Circulation, vol. 105, no. 4, pp. 431-437, 2002.
    • [141] X. Li, R. Luo, X. Mo et al., “Polymorphism of ZBTB17 gene is associated with idiopathic dilated cardiomyopathy: a case control study in a Han Chinese population,” European Journal of Medical Research, vol. 18, no. 1, article 10, 2013.
    • [142] C. Andreasen, J. B. Nielsen, L. Refsgaard et al., “New population-based exome data are questioning the pathogenicity of previously cardiomyopathy-associated genetic variants,” European Journal of Human Genetics, vol. 21, no. 9, pp. 918-928, 2013.
    • [143] U. Philipp, A. Vollmar, and O. Distl, “Evaluation of six candidate genes for dilated cardiomyopathy in Irish wolofhunds,” Animal Genetics, vol. 39, no. 1, pp. 88-89, 2008.
    • [144] M. Lynne O'Sullivan, M. R. O'Grady, W. Glen Pyle, and J. F. Dawson, “Evaluation of 10 genes encoding cardiac proteins in Doberman Pinschers with dilated cardiomyopathy,” American Journal of Veterinary Research, vol. 72, no. 7, pp. 932-938, 2011.
    • [145] P. Stabej, P. A. J. Leegwater, S. Imholz et al., “eTh canine sarcoglycan delta gene: BAC clone contig assembly, chromosome assignment and interrogation as a candidate gene for dilated cardiomyopathy in Dobermann dogs,” Cytogenetic and Genome Research, vol. 111, no. 2, pp. 140-146, 2005.
    • [146] U. Philipp, A. Vollmar, and O. Distl, “Evaluation of the Titin-Cap Gene (TCAP) as candidate for dilated cardiomyopathy in Irish wolofhunds,” Animal Biotechnology, vol. 19, no. 4, pp. 231-236, 2008.
    • [147] M. A. Oyama and S. Chittur, “Genomic expression patterns of cardiac tissues from dogs with dilated cardiomyopathy,” American Journal of Veterinary Research, vol. 66, no. 7, pp. 1140- 1155, 2005.
    • Volume 2014
  • No similar publications.